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Abstract
Background: Hyponatremia is prognostic of higher mortality in some cancers but has not been well studied in
others. We used a longitudinal design to determine the incidence and prognostic importance of euvolemic and
hypervolemic hyponatremia in patients following diagnosis with lymphoma, breast (BC), colorectal (CRC), small cell
lung (SCLC), or non-small cell lung cancer (NSCLC).
Methods: Medical record and tumor registry data from two large integrated delivery networks were combined for
patients diagnosed with lymphoma, BC, CRC, or lung cancers (2002–2010) who had ≥1 administration of radiation/
chemotherapy within 6 months of diagnosis and no evidence of hypovolemic hyponatremia. Hyponatremia
incidence was measured per 1000 person-years (PY). Cox proportional hazard models assessed the prognostic value
of hyponatremia as a time-varying covariate on overall survival (OS) and progression-free survival (PFS).
Results: Hyponatremia incidence (%, rate) was 76 % each, 1193 and 2311 per 1000 PY, among NSCLC and
SCLC patients, respectively; 37 %, 169 in BC; 64 %, 637 in CRC, and 60 %, 395 in lymphoma. Hyponatremia
was negatively associated with OS in BC (HR 3.7; P = <.01), CRC (HR 2.4; P < .01), lung cancer (HR 2.4; P < .01),
and lymphoma (HR 4.5; P < .01). Hyponatremia was marginally associated with shorter PFS (HR 1.3, P = .07)
across cancer types.
Conclusions: The incidence of hyponatremia is higher than previously reported in lung cancer, is high in
lymphoma, BC, and CRC and is a negative prognostic indicator for survival. Hyponatremia incidence in
malignancy may be underestimated. The effects of hyponatremia correction on survival in cancer patients
require further study.
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Background
Hyponatremia, the most common electrolyte disturb-
ance in hospitalized patients, results from loss of body
sodium or potassium with secondary water retention
(hypovolemic); from relative or absolute excess of body
water (euvolemic, including syndrome of inappropriate
antidiuretic hormone secretion (SIADH)); and from
edema formation due to renal sodium and water reten-
tion (hypervolemic) [1, 2]. Hypovolemic hyponatremia
responds readily to volume repletion, while treatment
modalities in euvolemic and hypervolemic hyponatremia
are not well standardized [1]. Hyponatremia incidence
and prevalence vary greatly depending on the popula-
tion, the presence and type of malignancy, clinical
setting, and serum sodium cutoff point [3–5]. Its preva-
lence has been reported in 1.7 % of the general United
States (US) population and in 3.4 % of respondents who
identified themselves as having cancer [2]. Hyponatremia
incidence in cancer patients has been reported in as
many as 47 % of hospital admissions, [6] and the
frequency of moderate to severe hyponatremia in
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hospitalized patients can range from 24 to 50 %, depend-
ing on malignancy type [7].
To date, most studies of hyponatremia in cancer have
been performed primarily in hospitalized patients or in
patients after the occurrence of another clinical event,
eg, surgical resection, chemotherapy initiation [6–9].
These studies have largely been conducted in patients
with lung or hematologic cancers or as an analysis of
multiple cancer types in studies assessing the prognostic
effects of hyponatremia. However, little research has
been conducted in other highly prevalent cancers, such as
breast or colorectal cancer. Moreover, to our knowledge,
no study has examined the frequency and prognostic
impact of hyponatremia longitudinally, beginning with
the date of cancer diagnosis. The current study assessed
the incidence and prognostic importance of euvolemic
and hypervolemic hyponatremia on or after diagnosis
with breast cancer (BC), colorectal cancer (CRC), small




This retrospective cohort analysis combined medical
record and tumor registry data from two large, inte-
grated delivery networks (IDN) serving patients in the
Midwest (IDN 1) and MidAtlantic (IDN 2) regions of
the US. Both are not-for-profit, physician-led IDNs,
which together contain data for more than 7 million
patients. Patient anonymity and confidentiality were
preserved by de-identification of the database in compli-
ance with the Health Insurance Portability and Account-
ability Act of 1996. For IDN 1, the protocol was
approved by an institutional review board (IRB) and for
IDN 2, the production and delivery of de-identified data
was deemed exempt from IRB review.
Patients
Patients selected into the study were adults with BC,
CRC, SCLC, NSCLC, or lymphoma documented in their
respective cancer registry between December 1, 2002
and November 30, 2010 (IDN 1) or January 1, 2005 and
December 31, 2009 (IDN 2), provided that the cancer
stage was known, the patient met analytic case require-
ments, and had ≥1 administration of radiation or
chemotherapy ≤6 months of diagnosis. In addition, pa-
tients were required to meet continuous enrollment
thresholds in IDN1 (12 months prior to and ≥1 month
post cancer diagnosis) or continuous clinical activity
thresholds in IDN 2 (≥1 in-system contacts in the
12 months prior to and ≥3 in the 6 months post cancer
diagnosis). Patients who had insufficient or conflicting
documentation in their medical records, had registration
of a non-invasive tumor, received cancer-related therapy
outside of the IDN, or had hypovolemic hyponatremia
were excluded. Patients were followed until study end,
death, clinical trial entry, new primary cancer onset,
disenrollment (IDN 1), or end of continuous clinical activity
(IDN 2).
Analysis
The cohort was divided into patients who developed one
or more episodes of hyponatremia at any time during
follow-up and those who never developed hyponatremia
during follow-up. Hyponatremia, defined as a serum
sodium laboratory result ≤135 mEq/L, was captured as
a time-varying covariate since it could resolve and then
reoccur. A hyponatremia episode began on the first
abnormal test result date and was considered resolved
on the first of 2 subsequent normal results. Hyponatre-
mia incidence was measured per 1000 person years
(PY) of observation and reported with 95 % confi-
dence intervals (CIs).
Hyponatremia was classified as mild (131–135 mEq/L),
moderate (125–130 mEq/L), or severe (<125 mEq/L)
based on the lowest observed serum sodium value during
the episode and was then further classified as euvolemic,
hypervolemic, or hypovolemic based on a multi-stage
algorithm using existing electronic laboratory data, medi-
cation orders, and ICD-9-CM diagnosis files. The first
stage of the algorithm, which has not yet been validated,
identified cases of true hyponatremia based on serum
osmolality test results of <275 mOsm/kg ≤48 h of the
serum sodium result with no evidence of hyperglycemia.
The algorithm then divided patients into hypovolemic,
hypervolemic or euvolemic hyponatremia decision trees
based on ICD 9 CM diagnosis codes, disease history, and
urine osmolality values. The algorithm further seg-
mented euvolemia into “SIADH,” largely determined by
laboratory values, and “other euvolemic hyponatremia,”
assigned to patients that did not meet the criteria for
hypervolemic but had a history of hypothyroidism, adrenal
insufficiencies, psychogenic polydipsia, or diuretic use.
Patient demographics were captured as of the date of
cancer diagnosis. Baseline clinical characteristics were
captured during the 12 months prior to cancer diagnosis.
A 3-point universal performance status score (PS) com-
bined Eastern Cooperative Oncology Group (ECOG) and
Karnofsky Performance Status (KPS) scores [10]. Grade 1
PS (good) was comprised of ECOG PS 0–1 and KPS 80–
100; Grade 2 PS (fair) of ECOG PS 2 and KPS 60–70; and
Grade 3 PS (poor) of ECOG PS 3–4 and KPS 10–60. The
statistical significance of between-cohort differences in
categorical variables was evaluated using the chi-square
test. Continuous data were compared using the t-test. All
tests were two-tailed, with a significance level of p < 0.05.
The primary study outcome was overall survival (OS).
Mortality was ascertained from registry records and state
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death records. The secondary study outcome, progression
free survival (PFS), was recorded and reported for IDN1
only due to resource constraints. The definition for solid
tumor progression, modified from RECIST v1.1., [11] in-
cluded: recurrence in a disease-free person, stage progres-
sion in a patient with active disease, increase in existing
lesion size, occurrence of a new lesion, and “other.” Disease
progression in lymphoma, using Cheson criteria, [12] in-
cluded: occurrence of a new lesion, increase in positron
emission tomography uptake, increase in lymph node or
lesion size, recurrence in a disease free person, and “other.”
Survival in days was calculated separately for OS and
PFS, from the date of cancer diagnosis to the date of all
cause death (OS) or progression (PFS) in patients with the
event and until the first evidence of censoring or study
end for patients who were not known to have died or to
have experienced progression by the end of the study.
Kaplan-Meier life tables were used to estimate survival at
1, 3, and 5 years. A Cox Proportional Hazard model with
hyponatremia as a time-varying covariate was employed
to identify the independent prognostic factors associated
with an increased risk of death across all cancer types and
among patients in each individual cancer type.
Results
Patients
During accrual of the study sample (detailed in Fig. 1),
1758 patients met all study requirements from a pool of
15,564 patients in both IDNs. It should be noted that
456 patients with hypovolemic hyponatremia (3 %) were
excluded from the study because this type of hyponatre-
mia generally responds to treatment with intravenous
fluids, while hypervolemic and euvolemic hyponatremia
tend to be more difficult to diagnose and treat [1, 4, 13].
Additionally, intravenous hydration is often required for
many cancer therapies and its use may complicate analysis
in patients with hypovolemic hyponatremia [4]. Among
study-eligible patients, 71 % were female, with a mean
(SD) age of 60 (13.0) years and a mean (SD) follow-up
duration of 3.1 (2.7) years. Selected characteristics of the
study population are shown in Table 1. Patients who
developed hyponatremia on or after cancer diagnosis were
more likely to be male, white, and have a shorter follow-
up time (Table 1). They were also significantly more likely
to have lung cancer or CRC and less likely to have BC.
Across tumor types, the hyponatremic cohort was more
likely to have metastatic disease and a worse performance
status after cancer diagnosis.
Hyponatremia incidence
Across cancer types, 54 % had ≥1 episode of euvolemic
or hypervolemic hyponatremia episode (Fig. 2). The fre-
quency of hyponatremia was highest among patients
with NSCLC and SCLC (76 % each), and lowest among
patients with BC (37 %). The majority (84 %) of all hypo-
natremia episodes were mild. The incidence rate (IR) of
hyponatremia per 1000 PY was 385.5 (95 % CI, 369.2–
402.2), with individual rates of 169 (BC), 395 (lymph-
oma), 637 (CRC), 1193 (NSCLC), and 2311 (SCLC). The
mean (SD) number of hyponatremia episodes per patient
was 2.2 (1.9), ranging from a low of 1.9 in BC to a high of
2.7 in CRC. Median time to first hyponatremia episode
was 59 days, ranging from a low of 10 days in SCLC to a
high of 194 days in BC. Median duration of each hypona-
tremia episode was 16 days.
Across all cancer types, 284 patients (16 %) had ≥1
moderate or severe episode of hyponatremia. Moderate or
severe episodes occurred in 6 % of BC patients, 19 % of
both CRC and lymphoma patients, 27 % of NSCLC
patients, and 46 % of SCLC patients. Among patients with
≥1 moderate or severe hyponatremia episode, 58 % of
hyponatremia episodes were mild, 37 % were moderate,
and 6 % were severe. The mean (SD) number of hypona-
tremia episodes per patient was 2.9 (2.4), ranging from 2.4
for both BC and NSCLC to 3.9 for CRC. Median time to
first hyponatremia episode was 19 days, ranging from
4 days for SCLC to 105 days for BC. Mean duration of
Fig. 1 Study flow chart
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each hyponatremia episode ranged from 41 days for
patients with SCLC to 130 days for patients with BC.
Survival analysis
Across the studied cancer types, 27 % of patients died
during follow-up. SCLC patients had the highest propor-
tion of deaths at 86 % whereas BC patients had the
lowest at 5 %. Life table data presented in Table 2
characterizes OS, by cancer type, at 1, 3, and 5 years.
The Kaplan-Meier overall survival curves, across all
cancer types, are shown in Fig. 3. Cox model results are
presented graphically in Fig. 4a and 4b. Experiencing one
or more episodes of hyponatremia was associated with a
significant increase in the likelihood of death (HR 2.7,
95 % CI, 2.2–3.4; P < 0.01), as was having stage 3 (HR 2.0,
95 % CI, 1.5–2.7; P < 0.01) or stage 4 disease at diagnosis
(HR 5.9, 95 % CI, 4.4–7.9; P < 0.01), having a fair/
poor PS score at diagnosis (HR 2.8, 95 % CI, 1.8–4.2;
P < 0.01), or having an unknown PS at the time of
diagnosis (HR 1.5, 95 % CI, 1.2–1.8; P < 0.01). Devel-
oping hyponatremia was associated with significantly
increased likelihood of death in each cancer specific model,
except for SCLC: BC (HR 3.7, 95 % CI, 1.9–7.2; P < 0.01),










N = 1758 n = 815 n = 943
Demographic characteristics
Sex, n (%) <0.01
Male 503 (29) 145 (18) 358 (38)
Female 1255 (71) 670 (82) 585 (62)
Age group collapsed, n (%) 0.06
18–64 1108 (63) 533 (65) 575 (61)
≥65 650 (37) 282 (35) 368 (39)
Mean age (SD) 60.2 (13) 59.6 (13) 60.6 (13) 0.11
Race, n (%) 0.09
Asian 18 (1) 8 (1) 10 (1)
Black 340 (19) 179 (22) 161 (17)




≤$49,999 1030 (59) 480 (59) 550 (58)
$50,000–$69,999 460 (26) 197 (24) 263 (28)
≥$70,000 239 (14) 123 (15) 116 (12)
Diagnosis year, n (%) 0.02
2002–2004 270 (15) 146 (18) 124 (13)
2005–2007 869 (49) 386 (47) 483 (51)
2008–2010 619 (35) 283 (35) 336 (36)
Mean length of
follow-up, y (SD)
3.1 (3) 3.3 (3) 3.0 (3) 0.03
Clinical characteristics at baseline
Cancer type, n (%)
Breast 839 (48) 533 (65) 306 (32) <0.01
Colorectal 233 (13) 84 (10) 149 (16) <0.01
Colon 146 (8) 50 (61) 96 (10) <0.01
Rectal 87 (5) 34 (4) 53 (6) 0.16
Lung 485 (28) 117 (14) 368 (39) <0.01
Small cell 80 (5) 19 (2) 61 (7) <0.01
Non-small cell 405 (23) 98 (12) 307 (33) <0.01
Lymphoma 201 (11) 81 (10) 120 (13) 0.07
Hodgkins 29 (2) 12 (2) 17 (2) 0.59
Non-Hodgkins 172 (10) 69 (9) 103 (11) 0.08
Distant metastasis, n (%) 384 (22) 99 (12) 285 (30) <0.01
Any PS within 90 days
of diagnosis, n (%)
864 (49) 384 (47) 480 (51) 0.11
Grade 1: ECOG 0, 1;
KPS 80–100a
747 (87) 350 (91) 397 (83) <0.01
Grade 2: ECOG 2;
KPS 60–70a
78 (9) 26 (7) 52 (11) 0.04
Grade 3: ECOG 3, 4;
KPS 10–50a
39 (5) 8 (2) 31 (7) <0.01
Table 1 Demographic and clinical characteristics (Continued)
Clinical characteristics during follow-up
Distant metastasis, n (%) 513 (29) 120 (15) 393 (42) <0.01
PS, last observed
documentation, n (%)
1249 (71) 553 (68) 696 (74) <0.01
Grade 1: ECOG 0, 1;
KPS 80–100a
990 (79) 499 (90) 491 (71) <0.01
Grade 2: ECOG 2; KPS
60–70a
141 (11) 34 (6) 107 (15) <0.01
Grade 3: ECOG 3, 4;
KPS 10–50a
118 (9) 20 (4) 98 (14) <0.01
Hospice services, n (%) 129 (7) 21 (3) 108 (12) <0.01
First course surgical
resection, n (%)
1029 (62) 563 (72) 466 (52) <0.01
Any chemo and
hormonal therapies, n (%)
1410 (80) 595 (73) 815 (86) <0.01
Alkylating agentsb 547 (39) 269 (45) 278 (34) <0.01
Antimetabolitesb 427 (30) 113 (19) 314 (39) <0.01
Antitumor
antibioticsb
452 (32) 223 (38) 229 (28) <0.01
Hormone therapyb 594 (42) 318 (53) 276 (34) <0.01
Mitotic inhibitorsb 761 (54) 260 (44) 501 (62) <0.01
Platinum agentsb 512 (36) 114 (19) 398 (49) <0.01
Targeted therapiesb 375 (27) 124 (21) 251 (31) <0.01
Otherc 175 (10) 48 (6) 127 (13) <0.01
Abbreviations: ECOG Eastern Cooperative Oncology Group, KPS Karnofsky PS,
PS performance status, SD standard deviation, y year
aPercent of patients with any PS
bPercent of patients with any chemo or hormonal therapy
cOther treatments including immunotherapies and topoisomerases
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CRC (HR 2.4, 95 % CI, 1.3–4.7; P < 0.01), lung cancer (HR
2.4, 95 % CI, 1.8–3.2; P < 0.01), SCLC (HR 1.5, 95 % CI
0.82–2.8; P = 0.19), NSCLC (HR 2.8, 95 % CI 2.0–3.9; P <
0.01) and lymphoma (HR 4.5, 95 % CI, 1.8–11.5; P < 0.01)
(Fig. 4).
Twenty-five percent (n = 228) of patients in IDN 1 expe-
rienced disease progression during follow-up, ranging
from a low of 10 % in BC to a high of 65 % in SCLC. Mean
(SD) time to progression was 395 (512) days, shortest in
SCLC patients at 160 days and longest in patients with
BC at 763 days. PFS at 1, 3, and 5 years was 87, 81, and
78 %, respectively. Cox model results are presented in
Fig. 3. Experiencing one or more episodes of hypona-
tremia was not associated with a significant change in
PFS (HR 1.3, 95 % CI, 0.98–1.7; P = 0.07); however,
patients with stage 3 (HR 1.8 95 % CI, 1.3–2.7; P <
0.01), or stage 4 cancer at diagnosis (HR 6.4 95 % CI,
4.3–9.4; P < 0.01) were at increased likelihood to experi-
ence disease progression.
Discussion
This study combined administrative and medical record
data from two large healthcare delivery systems in the US
to ascertain the incidence of hypervolemic or euvolemic
Fig. 2 Proportion of patients with hyponatremia, by hyponatremia severity and cancer type
Table 2 Life tables depicting overall survival at 1, 3, and 5 years
Cancer type 1 year 3 year 5 year
OS, % All HN No HN All HN No HN All HN No HN
All cancer types 81 64 87 72 49 81 69 45 79
Breast cancer 98 95 99 97 92 97 94 89 95
Colorectal cancer 86 79 90 73 65 78 68 56 76
Colon cancer 85 78 88 69 62 72 63 53a 72
Rectal cancer 87 80 92 81 68 89 75 62a 85a
Lung cancer 45 39 51 22 16 29 17 11a 24
Non-small cell 49 39 56 26 18 32 19 12a 27
Small cell 30 40 18a 6a 6a 8a 6a 6a 8a
Lymphoma 87 79 92 84 71 91 82 67 91
Hodgkins 100 100a 100 96 88a 100 96a 88a 100a
Non-Hodgkins 85 76 91 82 68 89 80 64 89
Abbreviation: HN hyponatremia
aEffective sample size for the year in question is ≤10 patients
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hyponatremia after cancer diagnosis and to assess its
prognostic importance on OS and PFS. Study findings sug-
gest that the incidence of hyponatremia among patients
with NSCLC and SCLC is higher than previously reported,
that the incidence of hyponatremia in BC, CRC, and
lymphoma is high, and that the occurrence of hyponatremia
in all 4 types of cancer is a negative prognostic indicator.
The incidence of hyponatremia in cancer patients varies
greatly depending on cancer type, clinical setting, and the
serum sodium threshold employed [3–5, 14]. Malignancy-
related SIADH due to ectopic secretion of arginine vaso-
pressin manifesting as euvolemic hyponatremia is most
commonly seen in patients with SCLC, but can also be
associated with other malignancy types [3–5]. In addition,
antineoplastic and cancer therapy palliative drugs are also
known to cause hyponatremia and many are directly associ-
ated with SIADH [3–5]. Other underlying conditions, such
as pain and nausea, or routine hospital treatments may also
cause hyponatremia, contributing to disease complexity.
Study findings suggest that the hyponatremia incidence
among patients with lung cancer is higher than previ-
ous reported. Hyponatremia occurred in 76 % of lung
cancer patients in the current study, considerably
higher than 20–50 %, as previously reported [7, 15–18].
This difference in incidence may be greater than observed
because the current study excluded patients with hypo-
volemic hyponatremia, while previously published studies
did not. However, previous studies also characterized
Fig. 3 Kaplan Meier plot of overall survival across cancer types
Fig. 4 Overall survival and progression-free survival across cancer types
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hyponatremia incidence upon the occurrence of a specific
clinical event such as hospitalization, surgical resection or
chemotherapy. As such, the measurement of hyponatre-
mia in these studies did not include hyponatremia in pa-
tients who did not experience the study-qualifying event
(eg resection), or who experienced hyponatremia prior to
the qualifying event. Differences in incidence between
SCLC and NSCLC subgroups did exist in the current
study. Forty-six percent of SCLC patients experienced an
episode of moderate/severe hyponatremia (vs 27.4 %
NSCLC) with the IR per thousand PY almost twice as high
among SCLC patients (2311 vs 1193).
Results from the current study also suggest that hypo-
natremia incidence in patients with CRC, lymphoma,
and BC is noteworthy, occurring in 64, 60, and 36 % of
patients at an IR per 1000 PY of 637, 395, and 169, re-
spectively. While most hyponatremia episodes in these
patients were mild, moderate to severe hyponatremia oc-
curred in 19 % of CRC and lymphoma patients and in
6 % of BC cases. As was observed in lung cancer, hypo-
natremia incidence is higher in this study than has been
previously reported, ie, 24 % of BC, 27 % of lymphoma
and 28 % of CRC patients [7, 19].
Hyponatremia has been correlated with shorter survival
in a number of studies, although too few studies have been
conducted in a given cancer type to support meta-
analyses [3, 7, 17–21]. The current study adds to the
growing body of literature in lung cancer and lymphoma,
and helps to establish preliminary results in CRC and BC.
Current study findings confirm the prognostic importance
of hyponatremia in lung cancer. The hazard ratio (95 %
CI, P value) associated with hyponatremia in the OS lung
cancer model was 2.4 (1.8–3.2, P < 0.01). Findings in the
SCLC specific model did not reach statistical significance,
but these were constrained by sample size. Findings in the
NSCLC-specific model were significant and are generally
higher than those previously reported [3, 21]. The current
study is also one of the first to establish the prognostic
importance of hyponatremia on OS in lymphoma, CRC,
and BC. A recent CRC study concluded that patients with
mild (HR 1.7), moderate (HR 2.2), and severe (HR 2.2)
hyponatremia upon hospitalization had significantly
shorter survival (P < 0.001) [19]. These findings are also
consistent with a recent meta-analysis which evaluated
the prognostic importance of the correction of hyponatre-
mia across a variety of clinical conditions, including all
forms of malignancy [22].
Study findings also suggest that hyponatremia may
impact PFS. However, PFS was collected only at a single
research site and model development, across cancer
types, was constrained by sample size and number of
events. However, our results are consistent with a study
by Tiseo et al. of hyponatremia in SCLC, in which PFS
in the univariate model did not meet significance, but
did show a trend of correlation between hyponatremia
and PFS (HR = 1.23, 95 % CI 0.97–1.55; P = 0.085) [21].
Although hyponatremia is associated with a poorer
prognosis in cancer patients, as in other diseases, there
are still questions as to whether hyponatremia is a marker
of disease severity, as evidenced in studies in palliative-
care patients, [8, 23] or if correction of hyponatremia can
lead to overall patient benefits, including survival [24–26].
A recent meta-analysis has suggested that correction of
hyponatremia improves survival, particularly in patients
who are corrected >130 mEq/L [22]. Additionally, findings
from a subsequent study suggest that correction of so-
dium level in cancer patients with severe hyponatremia fa-
cilitates additional treatment, and results in significantly
greater OS, although the authors note that a causal rela-
tionship could not be established [20]. Little is known
about the actual mechanism by which hyponatremia influ-
ences a poorer prognosis. Underlying renal and/or endo-
crine dysfunction, more aggressive biological behavior of
cancer cells that produce antidiuretic hormone (ADH),
and the effects of higher than normal levels of ADH over-
all are all plausible potential explanations. Although our
study suggests that hyponatremia is an adverse prognostic
factor in a multivariate statistical analysis, it is unclear if
hyponatremia is the result of multiple pathophysiological
effects, or an independent biological factor. Additional re-
search is needed to further elucidate these theories.
While the study sample was comparatively large, it was
not a random sample and the sources of the data are
worth reviewing. Although IDN1 and IDN2 each repre-
sent geographically constrained areas, they represent care
delivered by some of the largest and best delivery net-
works within the US. Results, as such, may not generalize
to care provided in other areas of the US, from smaller
delivery networks or those not associated with academic
medical centers. The IDN1 sample only included mem-
bers of their wholly owned insurance plan and excluded
Medicaid patients and the uninsured. While IDN2 pa-
tients were not restricted based on payer, it is possible that
data capture may have been incomplete if out of network
care was not documented. In addition, the classification of
hyponatremia type was assigned using a multi-stage algo-
rithm, which has not yet been validated. Accordingly, it is
possible that patients excluded from the analysis due to
hypovolemic hyponatremia may have been erroneously
excluded. It should be further noted that assignment
of disease progression was based on modified RECIST
1.1 and Cheson criteria and study results may vary
from clinical − trial-based protocols.
Conclusion
It has been shown that the incidence of hyponatremia is
high, not only in lung cancer, but also in patients with
lymphoma, BC, and CRC. Additionally, the occurrence
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of hyponatremia in all four types of cancer is associated
with poorer OS. An awareness of hyponatremia in can-
cer is important as it is commonly underestimated by
oncologists due to the difficulty of its interpretation
[4]. Further studies are warranted to explore the effects
of correction of hyponatremia on survival in cancer
patients.
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